Filtered By:
Condition: Aortic Stenosis

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 1228 results found since Jan 2013.

Impact of Concomitant Coronary Artery Disease on Atherosclerotic Plaques in the Aortic Arch in Patients With Severe Aortic Stenosis
ConclusionsIn patients with severe AS, concomitant CAD is associated with severe atherosclerotic burden in the aortic arch. This observation suggests that AS patients with concomitant CAD are at a higher risk for stroke, and that careful evaluation of complex arch plaques by TEE is needed for the risk stratification of stroke in these patients.
Source: Clinical Cardiology - April 12, 2013 Category: Cardiology Authors: Suwako Fujita, Kenichi Sugioka, Yoshiki Matsumura, Asahiro Ito, Takeshi Hozumi, Takao Hasegawa, Akihisa Hanatani, Takahiko Naruko, Makiko Ueda, Minoru Yoshiyama Tags: Clinical Investigation Source Type: research

Transapical Aortic Valve Replacement for Severe Aortic Stenosis: Results From the Nonrandomized Continued Access Cohort of the PARTNER Trial.
CONCLUSIONS: Among the 975 patients in the NRCA-TA cohort, rates of major outcomes including death and stroke compared favorably with outcomes of PMA-TA and SAVR patients enrolled in the PARTNER trial. This trend toward improved outcomes may be attributed to improved patient selection, individual centers surmounting the procedural learning curve, and refinements in surgical technique. PMID: 23968764 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - August 20, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Dewey TM, Bowers B, Thourani VH, Babaliaros V, Smith CR, Leon MB, Svensson LG, Tuzcu EM, Miller DC, Teirstein PS, Tyner J, Brown DL, Fontana GP, Makkar RR, Williams MR, George I, Kirtane AJ, Bavaria JE, Mack MJ Tags: Ann Thorac Surg Source Type: research

Flow-Gradient Patterns in Severe Aortic Stenosis with Preserved Ejection Fraction: Clinical Characteristics and Predictors of Survival.
CONCLUSIONS: NF/LG severe AS with preserved EF exhibits favorable survival with medical management and impact of AVR on survival was neutral. LF/LG severe AS is characterized by a high prevalence of atrial fibrillation, heart failure and reduced survival, and AVR was associated with improved survival. These findings have implications for evaluation of AS severity and subsequent management. PMID: 24048203 [PubMed - as supplied by publisher]
Source: Circulation - September 18, 2013 Category: Cardiology Authors: Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka PA Tags: Circulation Source Type: research

Time to peak velocity of aortic flow is useful in predicting severe aortic stenosis
Echocardiography has been the gold standard method to evaluate the severity of aortic valvular stenosis (AS) in clinical practice. The calculation of aortic valve area (AVA) by continuity equation is reliable and has been extensively studied in past publications . To get the correct AVA by continuity equation, the following parameters must be reliably measured: 1) left ventricular (LV) outflow tract (LVOT) diameter (LVOTd); 2) pulsed wave Doppler signal of the blood flow in the LVOT; and 3) continuous wave Doppler signal of the blood flow at the stenotic aortic valve . However, these measurements could not always be satisf...
Source: International Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Sung Hea Kim, Je Sang Kim, Bum Sung Kim, Jinoh Choi, Sang-Chol Lee, Jae K. Oh, Seung Woo Park Tags: Online Letters to the Editor Source Type: research

Dynamic variables and fluid responsiveness in patients for aortic stenosis surgery
ConclusionsThe arterial pressure‐based variables had moderate predictive values before valve replacement, but it predicted fluid responsiveness well postoperatively. Pleth variability index did not predict fluid responsiveness preoperatively, and it had a moderate predictive value postoperatively. These results indicate that arterial pressure‐based dynamic variables have limited potential to guide fluid therapy in patients with aortic stenosis. Their ability to guide fluid therapy after aortic valve replacement seems better.
Source: Acta Anaesthesiologica Scandinavica - April 29, 2014 Category: Anesthesiology Authors: L. Ø. HØISETH, I. E. HOFF, O. A. HAGEN, S. A. LANDSVERK, K. A. KIRKEBØEN Tags: Original Article Source Type: research

Transapical Aortic Valve Implantation—An Australian Experience
Conclusion: Good short-term outcomes and low or zero mortality are achievable with transapical TAVI at an Australian institution.
Source: Heart, Lung and Circulation - December 6, 2013 Category: Cardiology Authors: Michael Seco, Gonzalo Martinez, Paul G. Bannon, Bruce L. Cartwright, Mark Adams, Martin Ng, Michael K. Wilson, Michael P. Vallely Tags: Original Articles Source Type: research

Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery
This study sought to evaluate the safety and efficacy of the CoreValve transcatheter heart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for surgery.BackgroundUntreated severe aortic stenosis is a progressive disease with a poor prognosis. Transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis is a potentially effective therapy.MethodsWe performed a prospective, multicenter, nonrandomized investigation evaluating the safety and efficacy of self-expanding TAVR in patients with symptomatic severe aortic stenosis with prohibitive risks for surgery. The primary ...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 12, 2014 Category: Cardiology Source Type: research

Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation
Conclusions Severity of CAD appears to be associated with impaired clinical outcomes at 1 year after TAVI. Patients with SS >22 receive less complete revascularization and have a higher risk of cardiovascular death, stroke, or MI than patients without CAD or low SS.
Source: European Heart Journal - October 1, 2014 Category: Cardiology Authors: Stefanini, G. G., Stortecky, S., Cao, D., Rat-Wirtzler, J., O'Sullivan, C. J., Gloekler, S., Buellesfeld, L., Khattab, A. A., Nietlispach, F., Pilgrim, T., Huber, C., Carrel, T., Meier, B., Juni, P., Wenaweser, P., Windecker, S. Tags: Valvular heart disease Source Type: research

Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve
ConclusionsThis third-generation device addresses major deficiencies of earlier valves in terms of ease of use, accuracy of positioning, and paravalvular sealing. The rates of mortality and stroke with transfemoral access are among the lowest reported and support further evaluation as an alternative to open surgery in intermediate-risk patients. (Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve [SAPIEN3]; NCT01808287)
Source: Journal of the American College of Cardiology - November 24, 2014 Category: Cardiology Source Type: research

Echocardiographic and clinical factors related to paravalvular leak incidence in low-gradient severe aortic stenosis patients post-transcatheter aortic valve implantation
Conclusions PVL remains a common complication after TAVI, related to adverse events in LGSAS patients. Aa and BNP levels remain the most important predictors of PVL.
Source: European Journal of Echocardiography - April 23, 2015 Category: Cardiology Authors: Chrysohoou, C., Hayek, S. S., Spilias, N., Lerakis, S. Tags: ORIGINAL ARTICLES Source Type: research

TCT 2015: Medtronic touts CoreValve TAVI real-world registry data
Update: Added data from study of new patient populations Medtronic (NYSE:MDT) said today it released the 1st real-world registry study of its CoreValve transcatheter aortic valve implant, reporting outcomes in-line with its clinical trials of the device. The medtech giant also released new data from 3 studies focusing on new patient populations with significant comorbidities today. Data from all of the CoreValve studies was presented at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. The 6,160-patient Society of Thoracic Surgeons and American College of Cardiology TVT registry study repo...
Source: Mass Device - October 13, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Catheters Clinical Trials Medtronic TCT 2015 Source Type: news

Edwards Lifesciences hits all-time high on Sapien 3 study
Shares in Edwards Lifesciences (NYSE:EW) hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend. Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at the American College of Cardiology’s annual meeting April 3. The combined all-cause death & disabling stroke rate was 8.4% for TAVR with Sapien 3 and 16.6% for the surgery arm, according to the study, which was also published in The Lan...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves Wall Street Beat American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news

Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis
Conclusions The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation. Trial Registration ClinicalTrials.gov #NCT01314313.
Source: European Heart Journal - July 20, 2016 Category: Cardiology Authors: Kodali, S., Thourani, V. H., White, J., Malaisrie, S. C., Lim, S., Greason, K. L., Williams, M., Guerrero, M., Eisenhauer, A. C., Kapadia, S., Kereiakes, D. J., Herrmann, H. C., Babaliaros, V., Szeto, W. Y., Hahn, R. T., Pibarot, P., Weissman, N. J., Leip Tags: TAVI Source Type: research

Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study
AbstractThe definition of non-valvular atrial fibrillation (NVAF) is controversial. We aimed to assess the impact of valvular heart disease on stroke prevention strategies in NVAF patients. The RAMSES study was a multicenter and cross-sectional study conducted on NVAF patients (ClinicalTrials.gov identifier NCT02344901). The study population was divided into patients with significant valvular disease (SVD) and non-significant valvular disease (NSVD), whether they had at least one moderate valvular disease or not. Patients with a mechanical prosthetic valve and mitral stenosis were excluded. Baseline characteristics and ora...
Source: Journal of Thrombosis and Thrombolysis - November 14, 2016 Category: Hematology Source Type: research

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research